Portal de Periódicos da CAPES

Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.

2012; National Institutes of Health; Volume: 35; Issue: 1 Linguagem: Inglês

Valentina Svicher, Claudia Alteri, Marco Aurélio Echart Montano, Roberta D’Arrigo, Massimo Andreoni, Gioacchino Angarano, Andrea Antinori, Guido Antonelli, Tiziano Allice, Maria Carla Re, Fausto Baldanti, Ada Bertoli, Marco Borderi, Enzo Boeri, Isabella Bon, Bianca Bruzzone, Anna Paola Callegaro, Maria Rosaria Capobianchi, Giampiero Carosi, Roberto Cauda, Francesca Ceccherini‐Silberstein, Massimo Clementi, Antonio Chirianni, Manuela Colafigli, Antonella d’Arminio Monforte, Andrea De Luca, Antonio Di Biagio, Giuseppe Di Nicuolo, Giovanni Di Perri, Massimo Di Pietro, Fabiola Di Santo, Lavinia Fabeni, Giovanni Fadda, Massimo Galli, William Gennari, Valeria Ghisetti, Maria Carla Re, Caterina Gori, Andrea Gori, Roberto Gulminetti, F Leoncini, Gaetano Maffongelli, Franco Maggiolo, Giuseppe Manca, Franco Gargiulo, Canio Martinelli, Renato Maserati, Francesco Mazzotta, Genny Meini, Valeria Micheli, Laura Monno, Cristina Mussini, Pasquale Narciso, Silvia Nozza, Stefania Paolucci, Giorgio Palù, Saverio Giuseppe Parisi, Giustino Parruti, Angela Rosa Pignataro, Michela Pollicita, Tiziana Quirino, Maria Carla Re, Giuliano Rizzardini, Rosaria Santangelo, Renzo Scaggiante, Gaetana Sterrantino, Ombretta Turriziani, Maria Linda Vatteroni, Laura Vecchi, Claudio Viscoli, Vincenzo Vullo, Maurizio Zazzi, Adriano Lazzarin, Carlo Federico Perno,

Cytomegalovirus and herpesvirus research

The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the routine clinical diagnostic-laboratory.Twelve local centres and 5 reference centres (previously cross-validated) were identified. For inter-center validation-procedure, 60 peripheral-blood mononuclear cells (PBMCs) aliquots from 45 HAART-treated patients were randomly chosen for population V3 sequencing on proviral-DNA at local HIV centre and at reference-laboratory. Viral tropism was predicted by Geno2Pheno algorithm (False Positive Rate [FPR] = 20%) as proposed by the European-Guidelines. Quantification of total HIV-1 DNA was based on a method described by Viard (2004).Quantification of HIV-1 DNA was available for 35/45 (77.8%) samples, and gave a median value of 598 (IQR:252- 1,203) copies/10 PBMCs. A total of 56/60 (93.3%) samples were successfully amplified by both the reference and the local virological centers. The overall concordance of tropism prediction between local and reference centers was 54/56 (96.4%). Results of tropism prediction by local centers were: 33/54 (61.1%) R5 and 21/54 (38.9%) X4/DM.There was high concordance in the genotypic tropism prediction based on proviral DNA among different virological centers throughout Italy. Our results are in line with other European studies, and support the use of genotypic tropism testing on proviral DNA in patients with suppressed plasma HIV-1 RNA candidate to CCR5-antagonist treatment.